Principal CQV Engineer, Jason Rossi, on 10 Common Challenges in Facility Design for Cell and Gene Therapy Production

What are the common pitfalls and solutions when designing a facility for cell and gene therapy production?

Cell and gene therapies have led to a wholesale shift in how manufacturers approach and implement cGMP operations. Aspects like processing considerations for biological material, smaller batch sizes, shorter viability windows, and new requirements for product and personnel safety led to the reimagining of the production facility.

In the April 2026 edition of Cleanroom Technology Magazine, AST Principal CQV Engineer Jason Rossi draws on over 20 years of experience, insights, and lessons learned to highlight best practices for the design and build of GMP sterile product manufacturing facilities for advanced therapeutics.

Read the article below: